+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
C

Actively Recruiting

This trial studies adults with anterior cruciate ligament ACL rupture who need reconstructive surgery. It compares two types of screws used for fixing the graft during ACL reconstruction a human allogeneic cortical bone screw called Shark Screw ACL and a conventional biocomposite screw Mecta. The goal is to see if the bone screw reduces bone tunnel widening and lowers the rate of graft re-rupture. Knee function scores before and after surgery are also recorded to assess outcomes. Participants undergo ACL reconstruction with either the allogeneic bone screw or the biocomposite screw. The surgical technique is the same for both groups, including arthroscopic confirmation of diagnosis, tendon preparation, bone tunnel creation, graft insertion, and fixation with the assigned interference screw. The tibial bone tunnel is filled with cancellous chips, and graft stability is checked before wound closure. Participants have MRIs before surgery, within 3 days after surgery, and at 6, 12, and 24 months post-surgery. CT scans are done immediately after surgery, and at 6 and 24 months. Knee scores IKDC, KOOS, Lysholm, Tegner are collected before surgery and at 6, 12, and 24 months. The study measures bone tunnel widening in millimeters over time and evaluates graft incorporation, safety, and knee function. Total participation lasts 24 months after surgery.

Age: 18Years +All GendersPhase Not Applicable
1 location
R

Actively Recruiting

Researchers are evaluating a treatment for advanced breast cancer characterized by positive estrogen receptors, negative HER2 status, and mutations in the ESR1 gene. This study focuses on patients whose cancer has progressed despite prior endocrine therapy and treatment with CDK46 inhibitors. The main goal is to assess how well the combination of elacestrant and everolimus works compared to elacestrant alone in controlling the disease. Participants will be randomly assigned to one of two groups. One group receives daily oral doses of elacestrant and everolimus, while the other receives elacestrant plus a placebo resembling everolimus. Treatment continues in 28-day cycles until the disease progresses, unacceptable side effects occur, or other reasons lead to stopping treatment. After stopping, patients enter a follow-up period lasting up to 12 months where survival and new treatments are tracked every three months. During the study, patients will undergo tumor assessments, clinical evaluations, and quality-of-life questionnaires. Researchers will monitor treatment effects, side effects, and changes in health status. Safety is closely observed through regular tests including blood work and heart function monitoring. The total participation duration may extend up to about a year from treatment start to study completion.

Age: 18Years +All GendersPhase 3
104 locations